Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Dysbiosis of the Gut Microbiota

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...

Functions of the Gut Microbiota

Functions of the Gut Microbiota

The gut microbiota includes trillions of microorganisms that colonize the human gastrointestinal tract, including bacteria, archaea, viruses, and fungi. This complex ecosystem plays a critical role in maintaining intestinal and systemic health. Most of these microbes inhabit the large intestine, establishing a relatively stable and diverse community that contributes to gut homeostasis through various metabolic, immunological, and protective mechanisms.Dominant bacterial phyla, such as...

Microbiota of the Large Intestine

Microbiota of the Large Intestine

The large intestine hosts the most densely populated microbial ecosystem in the human body. This complex community primarily consists of anaerobic bacteria, with Bacillota (formerly Firmicutes) and Bacteroidota (formerly Bacteroidetes) as the predominant groups. The distribution of these microbes varies along different sections of the large intestine, influenced by local environmental factors such as oxygen availability and nutrient composition.The cecum, located at the beginning of the large...

Probiotics

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Scapular belt for the treatment of comminuted fractures of scapula].

Zhongguo gu shang = China journal of orthopaedics and traumatology·2010

Same author

Manipulation of ordered nanostructures of protonated polyoxometalate through covalently bonded modification.

Chemistry (Weinheim an der Bergstrasse, Germany)·2010

Same author

Developments in nonsteroidal antiandrogens targeting the androgen receptor.

ChemMedChem·2010

Same author

Dynamic presentation of immobilized ligands regulated through biomolecular recognition.

Journal of the American Chemical Society·2010

Same author

[Research on crop-weed discrimination using a field imaging spectrometer].

Guang pu xue yu guang pu fen xi = Guang pu·2010

Same author

A palladium/copper bimetallic catalytic system: dramatic improvement for Suzuki-Miyaura-type direct C-H arylation of azoles with arylboronic acids.

Chemistry (Weinheim an der Bergstrasse, Germany)·2010

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Butyrate-Producing Bacteria in Intestinal Disease Therapy: Potential and Challenges.

Fenfen Zhang¹, Wei Zhang¹, Xiaoting Ren¹

¹School of Clinical Medicine, Gansu Medical College, Pingliang, Gansu Province, China.

Biotechnology Journal

|June 17, 2026

Summary

This summary is machine-generated.

Butyrate-producing bacteria are crucial for gut health, fueling colonocytes and modulating immunity. Therapeutic use faces challenges like oxygen sensitivity, but innovative strategies offer a path forward for treating intestinal diseases.

Keywords:

butyrate‐producing bacteria inflammatory bowel disease live biotherapeutic products microbiome therapeutics short‐chain fatty acids

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Area of Science:

Microbiology
Gastroenterology
Immunology

Background:

Butyrate-producing bacteria are key to gut homeostasis.
They provide energy for colonocytes and modulate immunity.
Depletion of these bacteria is linked to various diseases.

Purpose of the Study:

To review the role of butyrate-producing bacteria in intestinal health.
To examine the therapeutic potential and challenges of butyrate-based therapies.
To explore novel strategies for overcoming translational bottlenecks.

Main Methods:

Literature review synthesizing current understanding.
Critical examination of mechanistic rationale and clinical associations.
Evaluation of cutting-edge strategies for therapeutic development.

Main Results:

Butyrate producers offer benefits via colonocyte energy, mucosal hypoxia, and immune modulation.
Therapeutic translation is hindered by oxygen sensitivity and ecological complexity.
Host context influences butyrate's effects.

Conclusions:

Despite challenges, innovative approaches like consortia and precision prebiotics show promise.
Overcoming bottlenecks is essential for developing evidence-based butyrogenic therapies.
These therapies could complement existing treatments for intestinal diseases.